188 related articles for article (PubMed ID: 28415580)
21. Nuclear receptor binding SET domain protein 1 promotes epithelial-mesenchymal transition in paclitaxel-resistant breast cancer cells via regulating nuclear factor kappa B and F-box and leucine-rich repeat protein 11.
Chen Y; Tang W; Zhu X; Zhang L; Zhu Y; Xiao H; Xu J; Fang Y; Li X; Tang C; Shi J
Bioengineered; 2021 Dec; 12(2):11506-11519. PubMed ID: 34905470
[TBL] [Abstract][Full Text] [Related]
22. Bifunctional fused polypeptide inhibits the growth and metastasis of breast cancer.
Liang AL; Qian HL; Zhang TT; Zhou N; Wang HJ; Men XT; Qi W; Zhang PP; Fu M; Liang X; Lin C; Liu YJ
Drug Des Devel Ther; 2015; 9():5671-86. PubMed ID: 26527862
[TBL] [Abstract][Full Text] [Related]
23. The mitotic kinase Aurora--a promotes distant metastases by inducing epithelial-to-mesenchymal transition in ERα(+) breast cancer cells.
D'Assoro AB; Liu T; Quatraro C; Amato A; Opyrchal M; Leontovich A; Ikeda Y; Ohmine S; Lingle W; Suman V; Ecsedy J; Iankov I; Di Leonardo A; Ayers-Inglers J; Degnim A; Billadeau D; McCubrey J; Ingle J; Salisbury JL; Galanis E
Oncogene; 2014 Jan; 33(5):599-610. PubMed ID: 23334326
[TBL] [Abstract][Full Text] [Related]
24. FGFR signaling maintains a drug persistent cell population following epithelial-mesenchymal transition.
Brown WS; Akhand SS; Wendt MK
Oncotarget; 2016 Dec; 7(50):83424-83436. PubMed ID: 27825137
[TBL] [Abstract][Full Text] [Related]
25. Garcinol regulates EMT and Wnt signaling pathways in vitro and in vivo, leading to anticancer activity against breast cancer cells.
Ahmad A; Sarkar SH; Bitar B; Ali S; Aboukameel A; Sethi S; Li Y; Bao B; Kong D; Banerjee S; Padhye SB; Sarkar FH
Mol Cancer Ther; 2012 Oct; 11(10):2193-201. PubMed ID: 22821148
[TBL] [Abstract][Full Text] [Related]
26. 14, 15-EET induces breast cancer cell EMT and cisplatin resistance by up-regulating integrin αvβ3 and activating FAK/PI3K/AKT signaling.
Luo J; Yao JF; Deng XF; Zheng XD; Jia M; Wang YQ; Huang Y; Zhu JH
J Exp Clin Cancer Res; 2018 Feb; 37(1):23. PubMed ID: 29426357
[TBL] [Abstract][Full Text] [Related]
27. Resveratrol reverses Doxorubicin resistance by inhibiting epithelial-mesenchymal transition (EMT) through modulating PTEN/Akt signaling pathway in gastric cancer.
Xu J; Liu D; Niu H; Zhu G; Xu Y; Ye D; Li J; Zhang Q
J Exp Clin Cancer Res; 2017 Jan; 36(1):19. PubMed ID: 28126034
[TBL] [Abstract][Full Text] [Related]
28. Epithelial to mesenchymal transition is associated with rapamycin resistance.
Holder AM; Akcakanat A; Adkins F; Evans K; Chen H; Wei C; Milton DR; Li Y; Do KA; Janku F; Meric-Bernstam F
Oncotarget; 2015 Aug; 6(23):19500-13. PubMed ID: 25944619
[TBL] [Abstract][Full Text] [Related]
29. Activation of IL-8 via PI3K/Akt-dependent pathway is involved in leptin-mediated epithelial-mesenchymal transition in human breast cancer cells.
Wang L; Tang C; Cao H; Li K; Pang X; Zhong L; Dang W; Tang H; Huang Y; Wei L; Su M; Chen T
Cancer Biol Ther; 2015; 16(8):1220-30. PubMed ID: 26121010
[TBL] [Abstract][Full Text] [Related]
30. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
31. Activation of histamine H4 receptors decreases epithelial-to-mesenchymal transition progress by inhibiting transforming growth factor-β1 signalling pathway in non-small cell lung cancer.
Cai WK; Hu J; Li T; Meng JR; Ma X; Yin SJ; Zhao CH; He GH; Xu GL
Eur J Cancer; 2014 Apr; 50(6):1195-206. PubMed ID: 24447834
[TBL] [Abstract][Full Text] [Related]
32. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.
Yoshida T; Ozawa Y; Kimura T; Sato Y; Kuznetsov G; Xu S; Uesugi M; Agoulnik S; Taylor N; Funahashi Y; Matsui J
Br J Cancer; 2014 Mar; 110(6):1497-505. PubMed ID: 24569463
[TBL] [Abstract][Full Text] [Related]
33. Isochlorogenic Acid C Reverses Epithelial-Mesenchymal Transition
Yu JK; Yue CH; Pan YR; Chiu YW; Liu JY; Lin KI; Lee CJ
Anticancer Res; 2018 Apr; 38(4):2127-2135. PubMed ID: 29599331
[TBL] [Abstract][Full Text] [Related]
34. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
35. WDR5 inhibition halts metastasis dissemination by repressing the mesenchymal phenotype of breast cancer cells.
Punzi S; Balestrieri C; D'Alesio C; Bossi D; Dellino GI; Gatti E; Pruneri G; Criscitiello C; Lovati G; Meliksetyan M; Carugo A; Curigliano G; Natoli G; Pelicci PG; Lanfrancone L
Breast Cancer Res; 2019 Nov; 21(1):123. PubMed ID: 31752957
[TBL] [Abstract][Full Text] [Related]
36. CXCR4 Signaling Induced Epithelial-Mesenchymal Transition by PI3K/AKT and ERK Pathways in Glioblastoma.
Lv B; Yang X; Lv S; Wang L; Fan K; Shi R; Wang F; Song H; Ma X; Tan X; Xu K; Xie J; Wang G; Feng M; Zhang L
Mol Neurobiol; 2015 Dec; 52(3):1263-1268. PubMed ID: 25326893
[TBL] [Abstract][Full Text] [Related]
37. IL-7 splicing variant IL-7δ5 induces EMT and metastasis of human breast cancer cell lines MCF-7 and BT-20 through activation of PI3K/Akt pathway.
Yang J; Zeng Z; Peng Y; Chen J; Pan L; Pan D
Histochem Cell Biol; 2014 Oct; 142(4):401-10. PubMed ID: 24770666
[TBL] [Abstract][Full Text] [Related]
38. Twist1-induced invadopodia formation promotes tumor metastasis.
Eckert MA; Lwin TM; Chang AT; Kim J; Danis E; Ohno-Machado L; Yang J
Cancer Cell; 2011 Mar; 19(3):372-86. PubMed ID: 21397860
[TBL] [Abstract][Full Text] [Related]
39. Activation of NF-κB by the RANKL/RANK system up-regulates snail and twist expressions and induces epithelial-to-mesenchymal transition in mammary tumor cell lines.
Tsubaki M; Komai M; Fujimoto S; Itoh T; Imano M; Sakamoto K; Shimaoka H; Takeda T; Ogawa N; Mashimo K; Fujiwara D; Mukai J; Sakaguchi K; Satou T; Nishida S
J Exp Clin Cancer Res; 2013 Sep; 32(1):62. PubMed ID: 24011086
[TBL] [Abstract][Full Text] [Related]
40. The N-terminal polypeptide derived from vMIP-II exerts its anti-tumor activity in human breast cancer by regulating lncRNA SPRY4-IT1.
Wu H; Wang Y; Chen T; Li Y; Wang H; Zhang L; Chen S; Wang W; Yang Q; Chen C
Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 30104400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
